Tähtinen M, Ranki A, Valle S L, Ovod V, Krohn K
University of Tampere, Finland.
Biomed Pharmacother. 1997;51(10):480-7. doi: 10.1016/s0753-3322(97)82330-x.
We describe the characterization of the B-cell epitopes of HIV-1 regulatory proteins Tat and Rev. The prevalence of antibodies to these proteins among human immunodeficiency virus (HIV)-1-infected individuals was examined by enzyme-linked immunosorbent assay (ELISA) and by Western blotting. The Tat and Rev antibody-positive sera were selected for epitope mapping performed with partially overlapping synthetic peptides bound to polyethylene pins. Eighteen and twelve percent of HIV-infected individuals had antibodies against Tat or Rev, respectively. In Tat, four epitopic regions were identified, situated within amino acids 6-10 (PRLEP), 21-37 (ACTNCYCKKCCFHCQVC), 39-58 (ITKALGISYGRKKRRQRRRA) and 74-82 (TSQSRGDPT). The most frequently recognized epitopic regions were located in the middle of the protein. In Rev, the two most frequently recognized epitopic regions were near the amino terminus of the protein within amino acids 12-20 (LIRTVRLIK) and 38-49 (RRNRRRRWRERQ). A third epitope was mapped around amino acids 55-62 (ISERILGT) and a fourth around amino acids 78-83 (LERLTU). To analyze the specificity of Tat and Rev epitopes, soluble synthetic peptides representing the identified epitopes were used in an ELISA assay, and the recognition of most epitopes was shown to be specific for HIV-1-infected individuals. In addition, many of the Tat and Rev epitopes were shown to overlap with regions having functional activity or with regions previously identified as T-cell epitopes.
我们描述了人类免疫缺陷病毒1型(HIV-1)调节蛋白Tat和Rev的B细胞表位的特征。通过酶联免疫吸附测定(ELISA)和蛋白质印迹法检测了人类免疫缺陷病毒(HIV)-1感染者中针对这些蛋白的抗体的流行情况。选择Tat和Rev抗体阳性血清,用于与结合在聚乙烯针上的部分重叠合成肽进行表位作图。分别有18%和12%的HIV感染者具有针对Tat或Rev的抗体。在Tat中,鉴定出四个表位区域,分别位于氨基酸6-10(PRLEP)、21-37(ACTNCYCKKCCFHCQVC)、39-58(ITKALGISYGRKKRRQRRRA)和74-82(TSQSRGDPT)。最常被识别的表位区域位于该蛋白的中部。在Rev中,两个最常被识别的表位区域靠近该蛋白的氨基末端,分别位于氨基酸12-20(LIRTVRLIK)和38-49(RRNRRRRWRERQ)。第三个表位定位在氨基酸55-62(ISERILGT)周围,第四个表位定位在氨基酸78-83(LERLTU)周围。为了分析Tat和Rev表位的特异性,在ELISA测定中使用了代表已鉴定表位的可溶性合成肽,结果显示大多数表位的识别对HIV-1感染者具有特异性。此外,许多Tat和Rev表位被证明与具有功能活性的区域或先前鉴定为T细胞表位的区域重叠。